Companies → Intuitive Surgical, Inc.
Save to list
Remove

Intuitive Surgical, Inc.

United States, California, Sunnyvale
Description
Intuitive Surgical is one of the pioneers of robotic-assisted surgery. The company develops the da Vinci Surgical System, a combination of software, hardware, and optics that allows doctors to perform robotically aided surgery from a remote console. The da Vinci system reproduces the doctor's hand movements during minimally invasive surgery in real time, performed by tiny electromechanical arms and instruments. The company's da Vinci products fall into five broad categories: da Vinci Surgical Systems, da Vinci instruments and accessories, da Vinci Stapling, da Vinci Energy, and da Vinci Vision, including Firefly Fluorescence imaging systems and da Vinci Endoscopes. It also provides a comprehensive suite of systems, learning, and services offerings. The US accounts for about 65% of the company's revenue.
Address:

1020 Kifer Rd Sunnyvale

CA

94086-5301 United States

Revenue
Recent news:

Is Intuitive Surgical, Inc. (ISRG) A Good Stock To Buy Now?

Is ISRG a good stock to buy? We came across a bullish thesis on Intuitive Surgical, Inc. on MTC’s Substack. In this article, we will summarize the bulls’ thesis on ISRG. Intuitive Surgical, Inc.’s share was trading at $483.46 as of March 16th. ISRG’s trailing and forward P/E were 59.99 and 47.39 respectively according to Yahoo Finance. Intuitive

Source: Insider Monkey Mar 21, 2026

Jim Cramer on Intuitive Surgical: “It’s Just Gotten Too Expensive Per Share”

Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the stocks mentioned during the show, as we cover everything Jim Cramer said about the oversold market. A caller asked which of the three metrics is most important for the company: procedure growth, system placements, or hospital utilization. Cramer replied: It’s hospital utilization, and what gets me down

Source: Insider Monkey Mar 21, 2026

Should You Continue to Hold Insulet Stock in Your Portfolio?

PODD's Omnipod 5 momentum and strong growth outlook highlight upside, but macro pressures and rising competition could challenge its near-term performance.

Source: Zacks Mar 20, 2026

Here's Why You Should Retain AMN HealthCare Stock in Your Portfolio

AMN rides MSP momentum, AI investments and surging labor disruption demand, but pricing pressure and volatile healthcare trends cloud its near-term outlook.

Source: Zacks Mar 20, 2026

GEHC Acquires Intelerad to Boost Cloud-First, AI Imaging Capabilities

GE HealthCare completes the $2.3B Intelerad deal to expand AI-driven imaging, boost recurring revenues and strengthen its cloud-first healthcare platform.

Source: Zacks Mar 20, 2026

Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments

GKOS launches Epioxa, the first FDA-approved topical keratoconus therapy, targeting an underserved market and positioning the company for long-term growth.

Source: Zacks Mar 20, 2026

NASDAQ - Delayed Quote - USD
ISRG
477.97 -1.96 (-0.41%)
At close March 20 20:00 UTC
482.01 +4.04 (+0.85%)
After hours: March 20 23:15 UTC
Candle
Line
1D
5D
1M
6M
1Y
5Y
Financial Statistics
Valuation Measures
Current
Quarterly
As of 03/20/2026
Market Cap: 169.76 B
Enterprise Value: 163.83 B
Trailing P/E: 60.73
Forward P/E: 47.62
PEG Ratio (5yr expected): 2.46
Price/Sales (ttm): 17.22
Price/Book (mrq): 9.52
Enterprise Value/Revenue: 16.28
Enterprise Value/EBITDA: 45.22
Financial Highlights
Profitability and Income Statement
Profit Margin: 28.38%
Return on Assets (ttm): 9.39%
Return on Equity (ttm): 16.69%
Revenue (ttm): 10.06 B
Net Income Avi to Common (ttm): 2.86 B
Diluted EPS (ttm): 7.89
Balance Sheet and Cash Flow
Total Cash (mrq): 5.93 B
Total Debt/Equity (mrq): 0.95%
Levered Free Cash Flow (ttm): 2.27 B
Disclaimer:

IndexBox is not affiliated with, associated with, or endorsed by this company in any way. The information provided on this page, including company details, is solely for informational purposes. IndexBox makes no representations or warranties about the accuracy or completeness of the information provided.

All data and information is provided “as is” for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. IndexBox is not an investment adviser, financial adviser or a securities broker. None of the data and information constitutes investment advice nor an offering, recommendation or solicitation by IndexBox to buy, sell or hold any security or financial product, and IndexBox makes no representation (and has no opinion) regarding the advisability or suitability of any investment.